239 related articles for article (PubMed ID: 22835778)
1. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy.
de Waure C; Capri S; Veneziano MA; Specchia ML; Cadeddu C; Di Nardo F; Ferriero AM; Gennari F; Hamilton C; Mancuso A; Quaranta G; Raponi M; Valerio L; Gensini G; Ricciardi W
Value Health; 2015 Jun; 18(4):457-66. PubMed ID: 26091600
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
5. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
10. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
Chen Z; Wang C; Xu X; Feng W
Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
[TBL] [Abstract][Full Text] [Related]
12. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.
Ilhan O; Arat M; Arslan O; Ayyildiz E; Sanli H; Beksac M; Ozcan M; Gürman G; Akan H
Transfus Apher Sci; 2004 Jun; 30(3):185-7. PubMed ID: 15172621
[TBL] [Abstract][Full Text] [Related]
16. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Skrepnek GH; Ballard EE
Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda B; Solana-Altabella A; Cano I; Acuña-Cruz E; Rodríguez-Veiga R; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Gómez I; Solves P; Lorenzo I; Piñana JL; Sanz J; Guerreiro M; Montoro Gómez J; Díaz-González A; Marco J; Blanco A; Sanz MÁ; Montesinos P
J Clin Apher; 2021 Aug; 36(4):612-620. PubMed ID: 33964038
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
[TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]